CN Mobile Logo

Search form




Angiosarcoma has generally poor survival among Asian patients; though chemotherapy can be effective, it has been underused in the last few decades.

Aldoxorubicin yielded significantly better progression-free survival over investigator’s choice of various chemotherapy options in patients with relapsed or refractory leiomyosarcoma and liposarcoma, according to updated results of a phase III trial.

A case study found that a patient with an inflammatory myofibroblastic tumor and a chromoplectic TPM3-ALK rearrangement that may be involved in tumorigenesis had a strong response to the ALK inhibitor ceritinib.

The use of a metronomic chemotherapy approach did not improve over standard chemotherapy in patients with high-grade, non-metastatic, operable osteosarcoma of the extremities.

A phase II trial found that the multikinase inhibitor regorafenib has clinical activity and offers improved progression-free survival in certain types of advanced soft-tissue sarcoma.

The FDA granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin for the treatment of soft-tissue sarcomas that is not amenable to curative treatment with radiotherapy or with surgery and with a histologic subtype treatable with anthracycline-containing regimens.

A trial of five rare sarcoma subtypes found that though dasatinib failed to achieve progression-free survival goals, more than half of patients with certain subtypes did have reasonably good survival outcomes.


Subscribe to Sarcoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.